LIXT vs. LITS, ENTX, IMUX, ASRT, IZTC, VXRT, UNCY, COEP, CRVO, and XBIT
Should you be buying Lixte Biotechnology stock or one of its competitors? The main competitors of Lixte Biotechnology include Lite Strategy (LITS), Entera Bio (ENTX), Immunic (IMUX), Assertio (ASRT), Invizyne Technologies (IZTC), Vaxart (VXRT), Unicycive Therapeutics (UNCY), Coeptis Therapeutics (COEP), CervoMed (CRVO), and XBiotech (XBIT). These companies are all part of the "pharmaceutical products" industry.
Lixte Biotechnology vs. Its Competitors
Lixte Biotechnology (NASDAQ:LIXT) and Lite Strategy (NASDAQ:LITS) are both small-cap pharmaceutical products companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, valuation, dividends, institutional ownership, analyst recommendations, risk, profitability and earnings.
5.1% of Lixte Biotechnology shares are held by institutional investors. Comparatively, 52.4% of Lite Strategy shares are held by institutional investors. 14.8% of Lixte Biotechnology shares are held by company insiders. Comparatively, 3.1% of Lite Strategy shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
In the previous week, Lite Strategy had 3 more articles in the media than Lixte Biotechnology. MarketBeat recorded 4 mentions for Lite Strategy and 1 mentions for Lixte Biotechnology. Lite Strategy's average media sentiment score of 0.78 beat Lixte Biotechnology's score of 0.00 indicating that Lite Strategy is being referred to more favorably in the news media.
Lixte Biotechnology has a beta of 0.48, indicating that its share price is 52% less volatile than the S&P 500. Comparatively, Lite Strategy has a beta of 0.36, indicating that its share price is 64% less volatile than the S&P 500.
Lixte Biotechnology has higher earnings, but lower revenue than Lite Strategy. Lixte Biotechnology is trading at a lower price-to-earnings ratio than Lite Strategy, indicating that it is currently the more affordable of the two stocks.
Lixte Biotechnology's return on equity of 0.00% beat Lite Strategy's return on equity.
Summary
Lite Strategy beats Lixte Biotechnology on 6 of the 11 factors compared between the two stocks.
Get Lixte Biotechnology News Delivered to You Automatically
Sign up to receive the latest news and ratings for LIXT and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding LIXT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Lixte Biotechnology Competitors List
Related Companies and Tools
This page (NASDAQ:LIXT) was last updated on 10/18/2025 by MarketBeat.com Staff
